Dominick Angiolillo has recieved honoraria for lectures by Bristol Myers Squibb; Sanofi-Aventis; Eli Lilly Co; Daiichi Sankyo, Inc.; honoraria for advisory board services to Bristol Myers Squibb ...

Dominick Angiolillo has recieved honoraria for lectures by Bristol Myers Squibb; Sanofi-Aventis; Eli Lilly Co; Daiichi Sankyo, Inc.; honoraria for advisory board services to Bristol Myers Squibb ...

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive ...

New approval brings the medicine to an earlier treatment setting and a broader patient population.

Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast ...

Jefferies analyst Stephen Barker maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on January 19 and set a price ...

Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39, on Monday ...

Daiichi Sankyo, an innovative global healthcare company, has established a state-of-the-art research laboratory in San Diego, California, US, dedicated to the development of robotics, automation and ...

(RTTNews) - The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult ...